<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Registration Process &#8211; Polypharma: Generics Developer</title>
	<atom:link href="https://polypharma.de/en/category/registration-process/feed/" rel="self" type="application/rss+xml" />
	<link>https://polypharma.de</link>
	<description>Full-service in the production of generics and delivery of raw materials in Africa and the Middle East</description>
	<lastBuildDate>Tue, 14 Sep 2021 09:20:13 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://polypharma.de/wp-content/uploads/2020/07/cropped-Polypharma-Technologies-and-Sciences-Hamburg-150x150.png</url>
	<title>Registration Process &#8211; Polypharma: Generics Developer</title>
	<link>https://polypharma.de</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Polypharma celebrates 30th Anniversary</title>
		<link>https://polypharma.de/en/2021/06/polypharma-celebrates-30th-anniversary/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Fri, 18 Jun 2021 08:27:42 +0000</pubDate>
				<category><![CDATA[Counterfeit Medicines]]></category>
		<category><![CDATA[Development / Dossiers]]></category>
		<category><![CDATA[Factory construction]]></category>
		<category><![CDATA[Fairs / Events]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Innovation]]></category>
		<category><![CDATA[Manufacturing Process]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Pharmaceutical Raw Materials / Laboratory Equipment]]></category>
		<category><![CDATA[Registration Process]]></category>
		<category><![CDATA[30 years]]></category>
		<category><![CDATA[30th anniversary]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[construction]]></category>
		<category><![CDATA[Consultant]]></category>
		<category><![CDATA[Developer]]></category>
		<category><![CDATA[Dossier development]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[Drug Master File]]></category>
		<category><![CDATA[food supplements]]></category>
		<category><![CDATA[generic manufacture]]></category>
		<category><![CDATA[MENA]]></category>
		<category><![CDATA[Middle East]]></category>
		<category><![CDATA[Polypharma]]></category>
		<category><![CDATA[Polypharma tech]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[raw material]]></category>
		<category><![CDATA[Sciences]]></category>
		<category><![CDATA[sourcing]]></category>
		<category><![CDATA[supply]]></category>
		<category><![CDATA[Technologies]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=8650</guid>

					<description><![CDATA[Single partner Polypharma offers a unique blend of services and skills that make it possible for it to act as a single partner accompanying local companies all the way from selection of target product through to actual receipt of raw materials for production. “Over the years we have developed more than 200 approved drug dossiers [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Learning curves in the current clinical biosimilar development</title>
		<link>https://polypharma.de/en/2020/05/learning-curves-in-the-current-clinical-biosimilar-development/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Wed, 20 May 2020 11:20:51 +0000</pubDate>
				<category><![CDATA[Registration Process]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6584</guid>

					<description><![CDATA[Many biosimilar developers need to think outside the box when structuring their clinical trials. As an example, one could discuss with a supervisor whether it is insufficient to investigate only one indication in the comparative efficacy study and rely on extrapolation for the remaining indications. https://www.biosimilardevelopment.com/doc/biosimilar-clinical-trials-past-present-and-near-future-0001?vm_tId=2217396&#38;user=89697b4a-1dcf-4952-afdc-6c787be708bf&#38;vm_alias=Biosimilar%20Clinical%20Trials%3A%20Past,%20Present,%20And%20(Near)%20Future%20&#38;utm_source=mkt_BIOS&#38;utm_medium=email&#38;utm_campaign=BIOS_06-04-2020&#38;utm_term=89697b4a-1dcf-4952-afdc-6c787be708bf&#38;utm_content=Biosimilar%20Clinical%20Trials%3A%20Past,%20Present,%20And%20(Near)%20Future%20&#38;mkt_tok=eyJpIjoiWTJKbU1XRTBOek0yTkdFdyIsInQiOiJGZldMcUI4Rm1kSWZ3V1l2VWZQdGF3SlZacTZkRUoyd2RkMEZTOWRlRWpnVTRJVFdXOUNvaUJrNkNCVUpZQVpveE9Va3FEUWxiRStiMjFnVVlLZTB2QUI5aUMzbnNuUUxHNk1TZ2gzczNiS3ltMTd1bWNrTm1kRGd1SEdxRjNBUiJ9]]></description>
		
		
		
			</item>
		<item>
		<title>Clinical tests of biosimilars in comparison to biopharmaceuticals</title>
		<link>https://polypharma.de/en/2020/05/clinical-tests-of-biosimilars-in-comparison-to-biopharmaceuticals/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Wed, 06 May 2020 11:16:06 +0000</pubDate>
				<category><![CDATA[Registration Process]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6574</guid>

					<description><![CDATA[Phase 3 clinical trials of biosimilars are beneficial for patients because they do not have to be afraid of receiving a placebo. They receive either the reference product or the biosimilar, so that they receive treatment in any case. In addition, it may be interesting for biosimilar developers to have studies conducted in countries where [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Is your internal strategy prepared for uncertainties in the development of biological drugs?</title>
		<link>https://polypharma.de/en/2020/03/is-your-internal-strategy-prepared-for-uncertainties-in-the-development-of-biological-drugs/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Thu, 19 Mar 2020 10:55:15 +0000</pubDate>
				<category><![CDATA[Registration Process]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6554</guid>

					<description><![CDATA[The pharmaceutical industry&#8217;s former dependence on blockbuster drugs has evolved to focus on developing drugs that address the unmet needs of smaller patient populations. These niche drugs are most commonly found in the form of biopharmaceuticals, which have accounted for an ever-increasing share of new drug approvals over the last ten years, from a low [&#8230;]]]></description>
		
		
		
			</item>
	</channel>
</rss>
